Patents by Inventor Georg Stingl

Georg Stingl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the detection of a latent tuberculosis infection
    Patent number: 11767566
    Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: September 26, 2023
    Assignees: Max-Planck-Gesellschaft, Medizinische Universität Wien
    Inventors: Julia Tornack, Stephen Reece, Fritz Melchers, Stefan H. E. Kaufmann, Wolfgang Bauer, Georg Stingl
  • METHODS FOR THE DETECTION OF A LATENT TUBERCULOSIS INFECTION
    Publication number: 20190226011
    Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.
    Type: Application
    Filed: June 6, 2017
    Publication date: July 25, 2019
    Applicants: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Medizinische Universität Wien
    Inventors: Julia Tornack, Steephen REECE, Fritz MELCHERS, Stefan H.E. KAUFMANN, Wolfgang BAUER, Georg STINGL
  • Elisa screening method for inhibitors of human IgE binding to the high affinity receptor, Fc&egr;RI&agr;
    Patent number: 6258549
    Abstract: The present invention is directed to an Assay for high capacity screening of substances interfering with the attachment of human IgE to its high affinity receptor and/or of substances capable of detaching already bound IgE from this receptor and for the differential analysis between autoimmune disorders and classical allergies.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: July 10, 2001
    Assignee: Novartis AG
    Inventors: Manfred Auer, Franz Hammerschmid, Georg Stingl